Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company, through its subsidiary, StemoniX, develops and manufactures at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. StemoniX, through collaborations with drug discovery organizations, tests compounds in-house, creates cell-based disease models, and operationalizes custom human iPSC-derived disease models for high-throughput screening. The company, through its subsidiary, vivoPharm, offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm specializes in conducting studies to guide drug development, starting from compound libraries and ending with a set of in vitro and in vivo data and reports, as needed for investigational new drug filings. The company is based in Cherry Hill, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: vyantbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/8/2022 | $5.00 → $4.00 | Buy | HC Wainwright & Co. |
| 10/6/2021 | $5.00 | Buy | HC Wainwright & Co. |
PRE 14A - Vyant Bio, Inc. (0001349929) (Filer)
15-12G - Vyant Bio, Inc. (0001349929) (Filer)
8-K - Vyant Bio, Inc. (0001349929) (Filer)
25 - Vyant Bio, Inc. (0001349929) (Filer)
8-K - Vyant Bio, Inc. (0001349929) (Filer)
10-K - Vyant Bio, Inc. (0001349929) (Filer)
EFFECT - Vyant Bio, Inc. (0001349929) (Filer)
EFFECT - Vyant Bio, Inc. (0001349929) (Filer)
EFFECT - Vyant Bio, Inc. (0001349929) (Filer)
EFFECT - Vyant Bio, Inc. (0001349929) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Vyant Bio, Inc. (0001349929) (Issuer)
4 - Vyant Bio, Inc. (0001349929) (Issuer)
4 - Vyant Bio, Inc. (0001349929) (Issuer)
4 - Vyant Bio, Inc. (0001349929) (Issuer)
4 - Vyant Bio, Inc. (0001349929) (Issuer)
4 - Vyant Bio, Inc. (0001349929) (Issuer)
4 - Vyant Bio, Inc. (0001349929) (Issuer)
4 - Vyant Bio, Inc. (0001349929) (Issuer)
4 - Vyant Bio, Inc. (0001349929) (Issuer)
4 - Vyant Bio, Inc. (0001349929) (Issuer)
Live Leadership Updates
Cherry Hill, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), an emerging global drug discovery company identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases, announced today the appointment of Robert T. Fremeau Jr., Ph.D., as Chief Scientific Officer. Dr. Fremeau is an experienced R&D leader with over two decades of drug discovery experience in academia and industry advancing next-gen drug development for severe neurological disorders. He is an accomplished scientist and biotech entrepreneur with an established history of scientific innovation and program leadership at the int
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
HC Wainwright & Co. reiterated coverage of Vyant Bio with a rating of Buy and set a new price target of $4.00 from $5.00 previously
HC Wainwright & Co. initiated coverage of Vyant Bio with a rating of Buy and set a new price target of $5.00
Fastest customizable press release news feed in the world
CHERRY HILL, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio's Board of Directors has filed its Certificate of Dissolution with the State of Delaware with an effective time of 5:00 p.m. on December 29, 2023, after which the Company's stock will cease trading on the OTC, and the holders of shares of the Company's common stock will cease to have any rights in respect of that stock, except the right of holders at such time to receive distributions, if any, purs
CHERRY HILL, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio's Board of Directors currently anticipates that it will file a Certificate of Dissolution with the State of Delaware in late December 2023, after which the Company's common stock will cease to trade and holders of shares of the Company's common stock will cease to have any rights in respect of that stock, except the right of holders at the date we file the Certificate of Dissolution to receive dist
CHERRY HILL, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT) is announcing the results of its special meeting of stockholders on November 1, 2023 (the "Special Meeting"). At the Special Meeting, Vyant Bio's stockholders, upon the unanimous recommendation of Vyant Bio's board of directors, voted in favor of the proposal to approve the voluntary liquidation and dissolution of the Company, pursuant to a Plan of Liquidation and Dissolution (the "Dissolution Proposal). The proposal received the affirmative vote of holders of 94.0% of the shares casting votes and 53.1% of the Company's total outstanding common shares. Vyant Bio's Board will determin
CHERRY HILL, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT) announced that it has completed the sale of all or substantially all of the assets of the Company (the "Sale") pursuant to an Asset Purchase Agreement dated July 13, 2023. ABOUT VYANT BIO, INC. Vyant Bio, Inc. (OTC:VYNT) has no continuing operating activities other than the winddown and closure of its business. The Company is currently seeking to obtain its shareholders' approval for the voluntary liquidation and dissolution of the Company, pursuant to a Plan of Liquidation and Dissolution. For more information, please visit Vyant Bio at: Internet: www.vyantbio.com Additional Inf
CHERRY HILL, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT) announced that its special meeting of stockholders on October 19, 2023 (the "Special Meeting") was reconvened resulting in the approval of the sale of all or substantially all of the assets of the Company. At the Special Meeting, Vyant Bio's stockholders, upon the unanimous recommendation of Vyant Bio's board of directors, voted in favor of the proposal to approve the sale of all or substantially all of the assets of the Company (the "Sale") pursuant to an Asset Purchase Agreement dated July 13, 2023. Vyant anticipates that the Sale will be consummated within the next week.
CHERRY HILL, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the "Special Meeting") was reconvened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposals as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on August 16, 2023 (the "Proxy Statement"). The adjourned Special Meeting will reconvene on October 19, 2023 at 11:00 a.m. Eastern Time at https://www.viewproxy.com/vynt/2023. The record date of August 4, 2023 for the adjour
CHERRY HILL, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the "Special Meeting") was reconvened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposals as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on August 16, 2023 (the "Proxy Statement"). The adjourned Special Meeting will reconvene on October 11, 2023 at 11:00 a.m. Eastern Time at https://www.viewproxy.com/vynt/2023. The record date of August 4, 2023 for the adj
CHERRY HILL, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT), today announced that its special meeting of stockholders on September 20, 2023 (the "Special Meeting") was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposals as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on August 16, 2023 (the "Proxy Statement"). The adjourned Special Meeting will reconvene on September 28, 2023 at 11:00 a.m. Eastern Time at https://www.viewproxy.com/vynt/2023. The record date of August 4, 2023 for the adjou
—Combines Three Leading Human Biomimetic Organoid Platform Technologies for Neurological Drug Discovery— —AxoSim Gains microBrain™ Intellectual Property from StemoniX, Along With Expert Scientific Team and Advanced R&D and Manufacturing Facility in Minnesota— —AxoSim to Begin Offering microBrain Products and Services Under Interim Distribution Agreement Effective Immediately— NEW ORLEANS and CHERRY HILL, N.J., July 17, 2023 /PRNewswire/ -- AxoSim, Inc., a leader in the development and application of human biomimetic platforms for neurological diseases, and Vyant Bio, Inc. (OTC:VYNT) (Vyant Bio) today announced that they have entered into a definitive agreement under which AxoSim will acquire
CHERRY HILL, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is a biotechnology company that incorporates innovative biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system ("CNS") drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. As previously announced, Vyant Bio filed a Form 25 with the Securities and Exchange Commission (the "SEC") on May 4, 2023 to voluntary delist its securities from The Nasdaq Capital Market ("Nasdaq"). Today, Vyant Bio announced that, followin
Live finance-specific insights
Q3 2022 and Recent Scientific and Business Highlights Completed the sale of its vivoPharm subsidiary to Reaction Biology Corporation for $5.5 million in an upfront cash paymentDelivered platform and poster presentations at the 2022 CDKL5 Forum hosted by the Loulou FoundationEntered into a master services agreement and related statement of work with an Australian CRO in November 2022 to support the Company's adult Rett Syndrome clinical trialProgress with licensing our iPSC technology to transition key product sales customers Q3 2022 Financial Highlights $9.4 million of cash and equivalents as of September 30, 2022Current cash balances, net proceeds from the sale of
~ Reaction Biology Acquires the Hershey, Pennsylvania-Based U.S. Operations of Vyant Bio Subsidiary vivoPharm PTY Ltd. ~ ~ Transaction Expands Reaction Biology's Capabilities to Provide Customers with Solutions in Both the Discovery and Development of New Drug Candidates ~ ~ Transaction Provides Vyant Bio with Additional Capital to Deploy into Further Development of its Therapeutic Pipeline in Genetic CNS Disorders ~ MALVERN, PA and CHERRY HILL, NJ, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reaction Biology Corporation ("Reaction"), an industry-leading provider of drug discovery services, and Vyant Bio, Inc. ("Vyant Bio") (NASDAQ:VYNT), an innovative biotechnology company reinventing drug
Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into clinical trials in Rett patients with encouragement and guidance from the International Rett Syndrome FoundationContinued progress with efforts towards the divestiture of the vivoPharm businessProgress with licensing our iPSC technology to transition key product sales customers Financial Highlights $11.7 million of cash and equivalents as of June 30, 2022Cash runway approximately 18 months CHERRY HILL, N.J., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (N
CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system ("CNS") drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will release its financial results for the second quarter and first half ended June 30, 2022, on Monday, August 22, 2022. Vyant Bio will host an investor conference call and webcast on Monday, August 22, 2022 at 4:30 pm ET. Jay Roberts, Chief E
CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system ("CNS") drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it is postponing its investor conference call for the second quarter and first half of 2022, originally scheduled for Monday, August 15, 2022 at 4:30 pm ET. Very recent developments related to the accounting for the potential sale of its vivoPharm s
CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system ("CNS") drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will release its financial results for the second quarter and first half ended June 30, 2022, on Monday, August 15, 2022. Vyant Bio will host an investor conference call and webcast on Monday, August 15, 2022 at 4:30 pm ET. Jay Roberts, Chief E
Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights ●Progress in the discovery of small molecule therapeutics to treat neurodevelopmental and neurodegenerative diseases for Rett Syndrome ("Rett"), CDKL5 Deficiency Disorder ("CDD"), and familial Parkinson's Disease ●Identification of a clinical candidate for Rett Syndrome through a robust rescue of disease phenotype in vitro using proprietary high throughput screening technology resulting in a potentially unique mechanism from other advanced therapeutic candidates ●Entered a collaboration with OrganoTherapeutics to accelerate 3D organoid disease modeling and identification of novel therapeutics
CHERRY HILL, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's central nervous system ("CNS") drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Monday, May 16, 2022. Jay Roberts, Chief Executive Officer, Andy LaFrence, Chief Financial Officer, and Robert Fremeau, PhD, Chief Scientific Officer, of Vyant Bio will provide an update on the busine
Highlights Focused as a pure-play drug discovery and development biotechnology companyPrimary work on the discovery of small molecule therapeutics to treat neurodevelopmental and neurodegenerative diseases for Rett Syndrome ("Rett"), CDKL5 Deficiency Disorder ("CDD"), and familial Parkinson's DiseaseStreamlined the business focus; pursuing the divestiture of wholly-owned subsidiary vivoPharm to exit CRO services business to focus on drug discoveryEntered into a strategic collaboration with Organo Therapeutics to accelerate 3D organoid disease modeling and identification of novel therapeutics to treat familial Parkinson's Disease in Q1, 2022Cash position at December 31, 2021 was $20.6 millio
CHERRY HILL, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's central nervous system ("CNS") drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Wednesday, March 30, 2022. Jay Roberts, Chief Executive Officer, Andy LaFrence, Chief Financial Officer and Robert T. Fremeau, PhD, Chief Scientific Officer of Vyant Bio will discuss the Year-End 2021
This live feed shows all institutional transactions in real time.
SC 13G/A - Vyant Bio, Inc. (0001349929) (Subject)
SC 13G - Vyant Bio, Inc. (0001349929) (Subject)
SC 13G/A - Vyant Bio, Inc. (0001349929) (Subject)
SC 13G/A - Vyant Bio, Inc. (0001349929) (Subject)
SC 13G/A - Vyant Bio, Inc. (0001349929) (Subject)